FDA Inspection 1258252 — UroGen Pharma, Inc.
The FDA completed an inspection of UroGen Pharma, Inc. on Dec 16, 2024 in Princeton, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Dec 16, 2024
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Princeton, NJ (United States)
Additional details
Sponsor, Contract Research Organization